Literature DB >> 24870806

Enhanced humoral immunity in mice lacking CB1 and CB2 receptors (Cnr1-/-/Cnr2-/- mice) is not due to increased splenic noradrenergic neuronal activity.

Tyrell Simkins1, Robert B Crawford, John L Goudreau, Keith J Lookingland, Barbara L F Kaplan.   

Abstract

Peripheral sympathetic noradrenergic neurons originating in the celiac mesenteric plexus have axons that terminate in close proximity to antibody-producing B cells in the spleen. Norepinephrine (NE) released from these neurons is reported to augment antibody production in response to an immune challenge via an action at the β2-adrenergic receptor (β2AR). Cannabinoids are immunosuppressive, and mice lacking CB1 and CB2 receptors (Cnr1(-/-)/Cnr2(-/-) mice) have augmented cell-mediated immune responses. The purpose of this study was to determine if Cnr1(-/-)/Cnr2(-/-) mice also exhibit enhanced humoral immunity and if that is associated with corresponding changes in noradrenergic neurons terminating in the spleen. The results reveal that IgM and IgG are enhanced in Cnr1(-/-)/Cnr2(-/-) mice as compared to WT both in immunologically naïve and lipopolysaccharide (LPS)-treated mice. While the elevated antibody production was correlated with increased expression of β2AR on splenic B cells and increased splenic capsule NE concentrations, the activity of noradrenergic neurons was suppressed in spleens from Cnr1(-/-)/Cnr2(-/-) mice as compared with WT controls. Together, these results suggest that Cnr1(-/-)/Cnr2(-/-) mice exhibit enhanced NE vesicular storage in axon terminals in these neurons, which might limit the NE available to bind β2AR on target cells, such as B cells. The results also demonstrate that enhanced antibody responses in the absence of CB1 and CB2 receptors are not due to increased sympathetic noradrenergic neuronal activity in the spleen.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24870806     DOI: 10.1007/s11481-014-9549-x

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  64 in total

1.  The level of IgE produced by a B cell is regulated by norepinephrine in a p38 MAPK- and CD23-dependent manner.

Authors:  Georg Pongratz; Jaclyn W McAlees; Daniel H Conrad; Robert S Erbe; Karen M Haas; Virginia M Sanders
Journal:  J Immunol       Date:  2006-09-01       Impact factor: 5.422

2.  Formation of B and T cell subsets require the cannabinoid receptor CB2.

Authors:  David Ziring; Bo Wei; Peter Velazquez; Matthew Schrage; Nancy E Buckley; Jonathan Braun
Journal:  Immunogenetics       Date:  2006-08-19       Impact factor: 2.846

Review 3.  Autonomic innervation and regulation of the immune system (1987-2007).

Authors:  Dwight M Nance; Virginia M Sanders
Journal:  Brain Behav Immun       Date:  2007-04-27       Impact factor: 7.217

4.  Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current.

Authors:  D Gebremedhin; A R Lange; W B Campbell; C J Hillard; D R Harder
Journal:  Am J Physiol       Date:  1999-06

5.  Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines.

Authors:  B B Brodie; E Costa; A Dlabac; N H Neff; H H Smookler
Journal:  J Pharmacol Exp Ther       Date:  1966-12       Impact factor: 4.030

6.  Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.

Authors:  D Shire; B Calandra; M Rinaldi-Carmona; D Oustric; B Pessègue; O Bonnin-Cabanne; G Le Fur; D Caput; P Ferrara
Journal:  Biochim Biophys Acta       Date:  1996-06-07

7.  Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation.

Authors:  N Niederhoffer; B Szabo
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

8.  Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.

Authors:  A R Schatz; M Lee; R B Condie; J T Pulaski; N E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  1997-02       Impact factor: 4.219

9.  Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.

Authors:  Alison E B Springs; Peer W F Karmaus; Robert B Crawford; Barbara L F Kaplan; Norbert E Kaminski
Journal:  J Leukoc Biol       Date:  2008-09-12       Impact factor: 4.962

10.  Effects of the selective dopaminergic D2 agonist quinelorane on the activity of dopaminergic and noradrenergic neurons projecting to the diencephalon of the rat.

Authors:  M J Eaton; K J Lookingland; K E Moore
Journal:  J Pharmacol Exp Ther       Date:  1994-02       Impact factor: 4.030

View more
  5 in total

Review 1.  Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.

Authors:  Matthew N Hill; Patrizia Campolongo; Rachel Yehuda; Sachin Patel
Journal:  Neuropsychopharmacology       Date:  2017-07-26       Impact factor: 7.853

2.  Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CB1 and CB2 Cannabinoid Receptors.

Authors:  Tyrell J Simkins; David Fried; Kevin Parikh; James J Galligan; John L Goudreau; Keith J Lookingland; Barbara L F Kaplan
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-10       Impact factor: 4.147

Review 3.  Role of adrenergic receptor signalling in neuroimmune communication.

Authors:  Sushanta Chhatar; Girdhari Lal
Journal:  Curr Res Immunol       Date:  2021-11-25

Review 4.  Bidirectional Role of β2-Adrenergic Receptor in Autoimmune Diseases.

Authors:  Li Wu; Yu Tai; Shanshan Hu; Mei Zhang; Rui Wang; Weijie Zhou; Juan Tao; Yongsheng Han; Qingtong Wang; Wei Wei
Journal:  Front Pharmacol       Date:  2018-11-27       Impact factor: 5.810

5.  Marijuana-Derived Cannabinoids Trigger a CB2/PI3K Axis of Suppression of the Innate Response to Oral Pathogens.

Authors:  Zhen Gu; Shilpa Singh; Rajarshi G Niyogi; Gwyneth J Lamont; Huizhi Wang; Richard J Lamont; David A Scott
Journal:  Front Immunol       Date:  2019-10-15       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.